Preferred Label : Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412;
NCIt synonyms : Anti-c-Met/EGFR/VEGF Antibody TAVO412; Anti-c-Met/Anti-EGFR/Anti-VEGF Trispecific Antibody TAVO412; Trispecific c-Met x EGFR x VEGF Antibody TAVO412; Anti-cMET/Anti-EGFR/Anti-VEGF Multi-specific Antibody TAVO412;
NCIt definition : A trispecific antibody targeting hepatocyte growth factor receptor (HGFR; c-Met),
epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF),
with potential anti-angiogenic and antineoplastic activities. Upon administration,
anti-c-Met/EGFR/VEGF trispecific antibody TAVO412 simultaneously targets and binds
to c-Met, EGFR and VEGF. The binding of TAVO412 to c-Met and EGFR expressed on tumor
cells prevents receptor phosphorylation. This prevents the activation of both c-Met-
and EGFR-mediated signaling pathways. The binding of TAVO412 to VEGF prevents both
its binding to VEGF receptors (VEGFRs) and VEGF/VEGFR-mediated signaling. This inhibits
the proliferation of vascular endothelial cells and prevents the growth and maintenance
of tumor blood vessels, which leads to tumor cell death. In addition, TAVO412 induces
Fc-mediated antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular
phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). EGFR and c-Met, both
upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor
cell proliferation. VEGF is overexpressed in a variety of cancer cells, and VEGF/VEGFR
signaling plays an essential role in angiogenesis and the proliferation, survival,
migration and differentiation of endothelial cells.;
Molecule name : TAVO-412; TAVO 412;
NCI Metathesaurus CUI : CL1912612;
Origin ID : C192641;
UMLS CUI : C5785344;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
